How the bacterium that plays role in spread of MRSA colonises the human nose

A collaboration between researchers at the School of Biochemistry and Immunology and the Department of Microbiology at Trinity College Dublin has identified a mechanism by which the bacterium Staphylococcus aureus (S. aureus) colonises our nasal passages. The study, recently published in the prestigious journal PLOS Pathogens, shows for the first time that a protein located on the bacterial surface called clumping factor B (ClfB) recognises a protein called loricrin that is a major component of the envelope of cells in the nose and skin.

S. aureus is an important , with the potential to cause severe invasive diseases. It is a major concern in hospitals and healthcare facilities, where many infections are caused by strains such as MRSA that are resistant to commonly used antibiotics. Interestingly, S. aureus persistently colonises about 20% of the human population by binding to skin-like cells within the . Being colonised predisposes an individual towards becoming infected so it is vital that we understand the mechanisms involved.

ClfB was previously shown to promote S. aureus colonisation in a human nasal volunteer study. This paper now identifies the mechanism by which ClfB facilitates S. aureus nasal colonisation. ClfB binding to loricrin was shown to be crucial for successful colonisation of the nose in a mouse model. A mouse lacking loricrin allowed fewer bacterial cells to colonise its nasal passages than a normal mouse. When S. aureus strains that lacked ClfB were used nasal colonisation was dramatically reduced. Finally it was shown that soluble loricrin could reduce binding of S. aureus to human nasal skin cells and that nasal administration of loricrin reduced S. aureus colonisation of mice.

Trinity's Assistant Professor at the School of Biochemistry and Immunology Rachel McLoughlin and Professor of Tim Foster, the study's corresponding authors concluded: "Loricrin is a major determinant of S. aureus nasal colonisation. This discovery opens new avenues for developing therapeutic strategies to reduce the burden of nasal carriage and consequently infections with this bacterium. This is particularly important given the difficulties associated with treating MRSA infections".

More information: Mulcahy, M. et al. (2012) Nasal Colonisation by Staphylococcus aureus Depends upon Clumping Factor B Binding to the Squamous Epithelial Cell Envelope Protein Loricrin. PLoS Pathog 8(12): e1003092. doi:10.1371/journal.ppat.1003092

add to favorites email to friend print save as pdf

Related Stories

Staphylococcus aureus: Why it just gets up your nose

Dec 27, 2012

A collaboration between researchers at the School of Biochemistry and Immunology and the Department of Microbiology at Trinity College Dublin has identified a mechanism by which the bacterium Staphylococcus aureus (S. au ...

MRSA skin infections up, linked to furunculosis

Jul 27, 2012

(HealthDay) -- The incidence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in the United States is increasing and is associated with follicular infection, most commonly follic ...

Coffee and tea consumption reduce MRSA risk

Jul 15, 2011

While an apple a day may keep the doctor away, new research published in the Annals of Family Medicine say that hot tea or coffee may keep the methicillin-resistant Staphyloccus aureus, or MRSA, bug away, or at least out of ...

Recommended for you

Long wait yet for Ebola vaccine: experts

18 minutes ago

It will be months, at least, before a vaccine becomes available to tackle Ebola, experts said Thursday as researchers reported success in early, safety tests with a leading candidate.

Sierra Leone to miss target for beating Ebola: UN

1 hour ago

The United Nations' Ebola response mission admitted Thursday it was going to miss its target for beating the deadly epidemic in Sierra Leone due to a chronic shortage of hospital beds.

Global Ebola toll rises to 5,689: WHO

5 hours ago

The World Health Organization said Thursday that the global death toll from the Ebola virus had increased to 5,689 out of a total of 15,935 cases of infection, mainly in western Africa.

Ebola vaccine promising in first human trials

16 hours ago

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.